Select Location
What is your delivery location?
We need your delivery location to continue browsing
Select Location
We need your delivery location to continue browsing
Prescription Required
Natco Pharma
28 tablet
Sofosbuvir and Velpatasvir
Keep in cold place
Delivering To:
Overview
Two antiviral medications are combined in Velpanat Tablet. Chronic hepatitis C virus (HCV) infection is treated with this prescription medication. To get rid of the infection, it battles the viruses. Two antivirals are combined to become Velpanat. The first once-daily single-tablet therapy with pangenotypic action is a combination of Velpatasvir and Sofosbuvir.
Hepatitis C
Chronic hepatitis C virus (HCV) infection
Velpanat tablets may cause certain side effects. If side effects occur after administration or last longer than usual, contact your healthcare professional.
Tiredness
Cough
Lower back pain
Skin rash
Headache
Nausea
Diarrhea
Muscle pain
Cramps, Loss of appetite
Anemia
Insomnia
Blurred vision
Take Velpanat tablets exactly as your healthcare provider tells you. Do not crush, chew, or break the tablet. Swallow as a whole. Seek emergency medical support in case of overdose.
Velpanat is a combination of velpatasvir & sofosbuvir. Sofosbuvir is a nucleotide analog NS5B polymerase inhibitor, and Velpatasvir is an NS5A replication complex inhibitor. Sofosbuvir is used in the treatment of genotype 1, 2, 3, and 4 HCV infection with different medicines, wherein the duration depends on the HCV genotype. Velpatasvir is a novel NS5A inhibitor. It has potent in vitro anti-HCV activity across all genotypes at the picomolar level. The effect of Sofosbuvir (Velpanat) 400 mg (recommended dosage) and 1200 mg (three times the recommended dosage) on QTc interval was calculated in an active-controlled (moxifloxacin 400 mg) thorough QT trial. Sofosbuvir (Velpanat) does not prolong QTc to any clinically relevant extent at a dose (three times the recommended dose). The effect of Velpatasvir (Velpanat) 500 mg (five times the recommended dosage) was calculated in an active-controlled (moxifloxacin 400 mg) thorough QT trial. Velpatasvir (Velpanat) does not prolong the QTc interval to any clinically relevant extent at a dose five times the recommended dose.
Alcohol
unsafe
It is advisable not to consume alcohol while taking this medicine.
Pregnancy
consult your doctor
Do not take Velpanat tablets without consulting the doctor, in case of pregnancy.
Breast Feeding
consult your doctor
Without a doctor's consultation, do not take this medicine if you're breastfeeding.
Driving
danger
It is advisable not to drive or operate heavy machinery, you may feel dizzy as one of the side effects of the medicine.
Kidney
caution
Do not take Velpanat tablets without a doctor's consultation in case of kidney problems.
Liver
caution
Share your medical history with the doctor in case of liver disease before taking this medicine.
Please consult your healthcare provider in case you miss a dose. Do not double the dose to cover up, unless your doctor tells you
Velpanat tablets are used in the treatment of chronic hepatitis C virus (HCV) infection.
Take this medicine exactly as your healthcare provider tells you. Do not chew, crush, or break it.
There can be side effects such as fever, dizziness, cough, diarrhea, nausea, insomnia, and anemia. Please contact your healthcare provider if you experience these or any other side effects.
Please consult your healthcare provider if you miss a dose. Do not adjust the dose as per your wish.
Avoid food items that can stress your liver, such as fatty or sugary foods.
The Velpanat tablet has proven effectiveness in treating hepatitis C in patients with compensated cirrhosis or advanced liver disease. The response rate could differ, though, and it's crucial to closely monitor liver function both before and after treatment.
The Velpanat tablet is safe and effective for those who have HIV and hepatitis C co-infection. To ensure proper control of both disorders, it is crucial to plan treatment with professionals in infectious diseases and HIV.
Feld, J. J., Jacobson, I. M., Hézode, C., Asselah, T., Ruane, P., Gruener, N., … Chan, H. L. Y. (2015). Sofosbuvir and velpatasvir for HCV genotype 1, 2, 4, 5, and 6 infection. New England Journal of Medicine, 373(27), 2599–2607. https://doi.org/10.1056/NEJMoa1512610.
Feld et al. (2015). Sofosbuvir and velpatasvir for HCV genotype 2 and 3 infection. New England Journal of Medicine, 373(27), 2608–2617. https://doi.org/10.1056/NEJMoa1512612.
Chandrashekhar et al. (2019). Sofosbuvir–velpatasvir single-tablet regimen administered for 12 weeks in a phase 3 study with minimal monitoring in India. Hepatology International. https://doi.org/10.1007/s12072‑019‑09927‑6 Chang Gung Medical Foundation (2021). Effectiveness of sofosbuvir/velpatasvir in patients with advanced fibrosis or cirrhosis: a population-based study in Taiwan. Infectious Diseases and Therapy.
Gaur, N. et al. (2019). Sofosbuvir–velpatasvir fixed-dose combination for treatment of chronic hepatitis C infection in patients with end-stage renal disease and kidney transplantation. Journal of Clinical and Experimental Hepatology, 10(3), 189–193.
Shah, V. et al. (2023). Sofosbuvir/velpatasvir/voxilaprevir for hepatitis C virus retreatment in difficult-to-treat patients: A real-life observational study from India. Journal of Clinical and Experimental Hepatology.
